Key result
Adjusted-dose warfarin reduces stroke and systemic embolism ~76% vs aspirin plus low-dose warfarin in AF with CKD.
Why the study?
Does adjusted-dose warfarin prevent ischemic stroke or systemic embolism in high-risk atrial fibrillation patients with stage 3 chronic kidney disease?
RCT (n=1,936)
open-label
randomly assigned to adjusted-dose warfarin versus aspirin plus fixed, low-dose warfarin
Yes
Does adjusted-dose warfarin prevent ischemic stroke or systemic embolism in high-risk atrial fibrillation patients with stage 3 chronic kidney disease?
Adjusted-dose warfarin is highly efficacious in reducing ischemic stroke and systemic embolism in high-risk atrial fibrillation patients with moderate chronic kidney disease, without significantly increasing major bleeding.
Answers are grounded in this paper and cite their sources.
Supports adjusted-dose warfarin for stroke prevention in high-risk AF with stage 3 CKD without excess bleeding; extends RCT evidence to moderate CKD.
BACKGROUND AND OBJECTIVES: The efficacy of adjusted-dose warfarin for prevention of stroke in atrial fibrillation patients with stage 3 chronic kidney disease (CKD) is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with stage 3 CKD participating in the Stroke Prevention in Atrial Fibrillation 3 trials were assessed to determine the effect of warfarin anticoagulation on stroke and major hemorrhage, and whether CKD status independently contributed to stroke risk. High-risk participants (n = 1044) in the randomized trial were assigned to adjusted-dose warfarin (target international normalized ratio 2 to 3) versus aspirin (325 mg) plus fixed, low-dose warfarin (subsequently shown to be equivalent to aspirin alone). Low-risk participants (n = 892) all received 325 mg aspirin daily. The primary outcome was ischemic stroke (96%) or systemic embolism (4%). RESULTS: Among the 1936 participants in the two trials, 42% (n = 805) had stage 3 CKD at entry. Considering the 1314 patients not assigned to adjusted-dose warfarin, the primary event rate was double among those with stage 3 CKD (hazard ratio 2.0, 95% CI 1.2, 3.3) versus those with a higher estimated GFR (eGFR). Among the 516 participants with stage 3 CKD included in the randomized trial, ischemic stroke/systemic embolism was reduced 76% (95% CI 42, 90; P < 0.001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively). CONCLUSIONS: Among atrial fibrillation patients participating in the Stroke Prevention in Atrial Fibrillation III trials, stage 3 CKD was associated with higher rates of ischemic stroke/systemic embolism. Adjusted-dose warfarin markedly reduced ischemic stroke/systemic embolism in high-risk atrial fibrillation patients with stage 3 CKD.
No takes yet. Share an insight, caveat, or question.
Hart et al. (2011) conducted an RCT in Atrial Fibrillation with moderate Chronic Kidney Disease (stage 3) (n=1,936). Adjusted-dose warfarin vs. Aspirin (325 mg) plus fixed, low-dose warfarin (1-3 mg daily) was evaluated on Ischemic stroke or systemic embolism (reduced 76%, 95% CI 42-90, p=<0.001). Adjusted-dose warfarin reduced ischemic stroke and systemic embolism by 76% compared with aspirin plus low-dose warfarin in high-risk atrial fibrillation patients with stage 3 chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: